輝瑞新冠口服藥測試療效顯着疫苗股捱沽 康希諾及騰盛博藥急挫15%-24%
美國兩大藥廠默克(MRK.US)及輝瑞(PFE.US)先後研發新冠口服藥臨牀試驗療效顯着,輝瑞上週五發布新冠口服藥臨牀試驗中期結果顯示能夠將患者住院和死亡風險大減八成九,刺激該股急漲近11%報48.61美元。
市場憂慮新冠疫苗需求下降,本港上市疫苗股捱沽,尤其是今年7月中旬才以每股22.25元上市的騰盛博藥-B(02137.HK)低見18.5元,創上市新低,現報19.24元,急挫24%。康希諾生物-B(06185.HK)低見153元,創近一年低,現報163.1元,急挫15%。
藍籌藥明生物(02269.HK)四連跌,最低見92.05元,創逾七個月低,現報93.75元,續挫8%,爲最傷藍籌。開拓藥業-B(09939.HK)低見33元,創逾半年低,現報37.45元,續跌6.1%。復星醫藥(02196.HK)低見32.55元,暫守穩10月所創低位31.6元,現報34元,跌6.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.